# Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia

> **NCT03288441** · — · UNKNOWN · sponsor: **Maastricht University Medical Center** · enrollment: 300 (estimated)

## Conditions studied

- Hematologic Neoplasms
- Thrombocytopenia
- Anticoagulants
- Platelet Aggregation Inhibitors

## Interventions

- **DRUG:** Hold
- **DRUG:** Prophylactic dose antithrombotic
- **DRUG:** Change antithrombotic Drug
- **BIOLOGICAL:** Change platelet transfusion threshold
- **DRUG:** Full dose antithrombotics
- **DEVICE:** Mechanical measures
- **DRUG:** Intermediate dose antithrombotic

## Key facts

- **NCT ID:** NCT03288441
- **Lead sponsor:** Maastricht University Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-20
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2020-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03288441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03288441, "Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03288441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*